Share

January 29, 2019; 92 (5) Article

Risk factors for possible REM sleep behavior disorder

A CLSA population-based cohort study

Chun Yao, Seyed-Mohammad Fereshtehnejad, Mark R. Keezer, Christina Wolfson, Amélie Pelletier, Ronald B. Postuma
First published December 26, 2018, DOI: https://doi.org/10.1212/WNL.0000000000006849
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
150

Share

Article Information

vol. 92 no. 5 e475-e485
DOI: 
https://doi.org/10.1212/WNL.0000000000006849
PubMed: 
30587514
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 11, 2018
  • Accepted in final form October 1, 2018
  • First Published December 26, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Chun Yao, MSc,
    2. Seyed-Mohammad Fereshtehnejad, MD, MPH, PhD,
    3. Mark R. Keezer, MDCM, PhD,
    4. Christina Wolfson, PhD,
    5. Amélie Pelletier, PhD and
    6. Ronald B. Postuma, MD, MSc
  1. Chun Yao, MSc,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Seyed-Mohammad Fereshtehnejad, MD, MPH, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Parkinson's Disease, Academic Editor, 2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) McGill University, Postdoctoral Fellowship, Canada First Research Excellence Fund for the Healthy Brains for Healthy Lives (HBHL) initiative (2) McGill University, Postdoctoral Fellowship, Richard and Edith Strauss Scholarship (3) McGill University, Postdoctoral Fellowship, Preston Robb Scholarship, Montreal Neurological Institute (MNI) (4) McGill University, Student Fellowship, McGill University Health Center (MUHC)

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Mark R. Keezer, MDCM, PhD,
    4. Scientific Advisory Boards:

    1. Eisai, Elsevier, Sunovion, Novartis, Sage Therapeutics, and UCB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Eisai and UCB

    Editorial Boards:

    1. Epilepsia

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. UCB and Eisai

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Savoy Foundation, Canadian Frailty Network, CRCHUM, CHUM Epilepsy Group

    Research Support, Foundations and Societies:

    1. Fondation du Jardin de l'Arbre de la Vie, Fondation du CHUM

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Christina Wolfson, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Military, Veteran and Family Health. Member of Editorial Board. 2014 to present.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Canadian Institutes of Health Research, Co-Principal Investigator/2015-2020. National Multiple Sclerosis Society,Principal Investigator/2013-2016

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Society of Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Amélie Pelletier, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Ronald B. Postuma, MD, MSc
    7. Scientific Advisory Boards:

    1. 2) Parkinson Study Group

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Boehringer-Ingelheim, Otsuku

    Editorial Boards:

    1. (1) Editorial Board, Movement Disorders Journal; 2014 - present (2) Editorial Board, Annals of Neurology - 2017 - present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. GE Health Care, Jazz, Novartis, Roche, Theranexus, Takeda, Biotie, Biogen,

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Fonds de la Recherche en Sante, Canadian Institute of Health Research, The Parkinson Society of Canada, Weston-Garfield Foundation, MIchael J. Fox Foundation, Webster Foundation,

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Michael J Fox Foundation, Webster Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Integrated Program in Neuroscience (C.Y.), Department of Neurology and Neurosurgery (S.-M.F., R.B.P.), Department of Epidemiology and Biostatistics and Occupational Health (C.W.), and Department of Medicine (C.W., A.P.), McGill University; Centre de Recherche du Centre hospitalier de l'Université de Montréal (M.R.K.); and Research Institute of the McGill University Health Centre (C.W., A.P.), Montreal, Quebec, Canada.
  1. Correspondence
    Dr. Postuma ron.postuma{at}mcgill.ca
View Full Text

Article usage

Article usage: December 2018 to July 2019

AbstractFullPdfSource
Dec 20181211012Highwire
Jan 201913022066Highwire
Feb 20193913826Highwire
Mar 20192792019Highwire
Apr 2019224129Highwire
May 201920463Highwire
Jun 201917178Highwire
Jul 2019123107Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me